Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

1743studies shown

Showing 757-768 of 1,743

Recruitment unclearEUCTR 2019-002213-19

A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolarity Pa...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

BipolarityDrug

Countries: United Kingdom
Sponsor: University of British Columbia
Condition: Bipolarity

View study

Recruitment unclearEUCTR 2017-002227-13

A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

SchizophreniaDrug

Countries: France, United Kingdom, Bulgaria, ...
Sponsor: ACADIA Pharmaceuticals Inc.
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2020-000341-14

A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in ...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

DepressionDrug

Countries: United Kingdom, Belgium, Bulgaria, ...
Sponsor: Janssen-Cilag International NV
Condition: Depression

View study

Recruitment unclearEUCTR 2017-001739-38

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

SchizophreniaDrug

Countries: United Kingdom
Sponsor: Takeda Development Centre Europe Ltd.
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2016-004973-42

A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early inter...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

SchizophreniaDrug

Countries: United Kingdom
Sponsor: Boehringer Ingelheim Limited
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2018-002740-82

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 wee...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

SchizophreniaDrug

Countries: United Kingdom
Sponsor: Boehringer Ingelheim Limited
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2018-002942-35

A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo and standard psychological care for depression in Parkinson’s Disease

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

DepressionDrug

Countries: United Kingdom
Sponsor: University College London Comprehensive Clinical Trials Unit
Condition: Depression

View study

Recruitment unclearEUCTR 2016-000118-31

A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

SchizophreniaBiological

Countries: United Kingdom
Sponsor: Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2020-000469-18

A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

DepressionDrug

Countries: United Kingdom
Sponsor: Initiator Pharma
Condition: Depression

View study

Recruitment unclearEUCTR 2018-003573-97

A randomised, placebo controlled trial of psilocybin in treatment resistant depression: A feasibility study

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

DepressionDrug

Countries: United Kingdom
Sponsor: King's College London [...] 1. King's College London 2. South London & Maudsley NHS Foundation Trust
Condition: Depression

View study

Recruitment unclearEUCTR 2018-001884-21

A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS-penetrant P2X7 receptor antagonist, JNJ-54175446, in people with major depressive disorder, an inc...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

DepressionDrug

Countries: United Kingdom
Sponsor: Cambridgeshire and Peterborough NHS Foundation Trust and University of Cambridge
Condition: Depression

View study

Recruitment unclearEUCTR 2013-004903-37

A RANDOMIZED, 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLEXIBLE DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN CHILDREN AND ADOLESCENT SUBJECTS WITH BIPOLAR I DEPR...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

Bipolarity, DepressionDrug

Countries: France, United Kingdom, Bulgaria, ...
Sponsor: SUNOVION PHARMACEUTICALS INC.
Condition: Bipolarity, Depression

View study

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.